DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR FAMCICLOVIR

All Clinical Trials for Famciclovir

Subscribe to access the full database, or Start Trial
Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00098046	Famciclovir Oral Pediatric Formulation in Children 1-12 Years of Age With Varicella Zoster Infection	Completed	Novartis	Phase 3	2005-07-01	Varicella zoster virus causes chickenpox in children and shingles in adults. Chickenpox is usually a self-limiting illness characterized by fever and a rash. Serious complications can include secondary bacterial infections, pneumonia, and encephalitis. Anti-viral treatment is not a standard of care in immunocompetent children, but is recommended whenever a risk of complication exists. This study will evaluate the safety and blood levels of a new formulation of famciclovir in children 1-12 years of age.
NCT00098059	Famciclovir Pediatric Formulation in Children 1 to 12 Years of Age With Herpes Simplex Infection	Completed	Novartis Pharmaceuticals	Phase 3	2005-02-01	This study will evaluate the safety and blood levels of a new pediatric formulation of Famvir in children 1-12 years of age. In Part A, patients will receive a single dose of famciclovir (12.5 mg/kg) to assess pharmacokinetics (PK) and safety. In Part B, patients will receive multiple doses of famciclovir alone or with concomitant oral anti-herpes therapy to assess safety and tolerability. Part B will start only after PK data from Part A had been analyzed.
NCT00129818	A Study to Evaluate the Effect of Famciclovir in Reducing Herpes Virus Shedding	Completed	Novartis	Phase 4	2004-07-01	The study is designed to assess the efficacy and safety of famciclovir 250 mg twice a day (bid) suppressive treatment in men and women with herpes virus type 2 (HSV-2) infection, with and without a reported history of genital herpes and with or without herpes virus type 1 (HSV-1) seropositivity.
NCT00171990	Efficacy and Safety of Oral Famciclovir in Patients With Active Recurrent Genital Herpes	Completed	Novartis	Phase 3	2003-01-01	This is a phase III, multicenter, randomized, double-blind, parallel-group study to compare the efficacy and safety of a two-day treatment with famciclovir (500 mg loading dose followed by 250 mg 12-hourly) to standard five-day treatment with famciclovir (125 mg 12-hourly) in patients with active recurrent genital herpes. This study is not recruiting patients in the United States.
NCT00219310	RELIEF: Randomized Episodic Versus Long-Term Suppression Experience With Famciclovir	Completed	Novartis	Phase 4	2003-06-01	This trial will assess whether RGH patients who have two recurrent episodes within a three month period would benefit from suppressive treatment and whether patients prefer episodic therapy or suppressive therapy for the treatment of their RGH.
>Trial ID	>Title	>Status	>Sponsor	>Phase	>Start Date	>Summary